Teyi Pharmaceutical Group Co.,Ltd
Shenzhen Stock ExchangeTotal Valuation
Teyi Pharmaceutical Group Co.,Ltd carries a market capitalization of 4.60B, placing it among publicly traded companies globally. Its enterprise value stands at 4.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.60B |
| Enterprise Value | 4.37B |
Share Statistics
Teyi Pharmaceutical Group Co.,Ltd currently has 512.63M shares outstanding.
| Shares Outstanding | 512.63M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Teyi Pharmaceutical Group Co.,Ltd trades at a trailing price-to-earnings ratio of 79.28. The price-to-sales ratio is 5.11, and the price-to-book ratio stands at 5.03.
| PE Ratio | 79.28 |
| PS Ratio | 5.11 |
| PB Ratio | 5.03 |
| P/TBV Ratio | 4.02 |
| P/FCF Ratio | 50.08 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Teyi Pharmaceutical Group Co.,Ltd trades at an EV/EBITDA multiple of 53.61 and an EV/FCF ratio of 47.33. The EV/Sales ratio of 5.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 53.61 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.05 |
| EV / EBITDA | 53.61 |
| EV / EBIT | 53.61 |
| EV / FCF | 47.33 |
Financial Position
Teyi Pharmaceutical Group Co.,Ltd maintains a current ratio of 1.76, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.48, indicating elevated leverage, while an interest coverage ratio of 16.23 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.76 |
| Quick Ratio | 0.78 |
| Debt / Equity | 17.48 |
| Debt / EBITDA | 3.80 |
| Interest Coverage | 16.23 |
Financial Efficiency
Teyi Pharmaceutical Group Co.,Ltd posts a return on equity of 6.46 and a return on invested capital of 3.02.
| Return on Equity (ROE) | 6.46 |
| Return on Assets (ROA) | 2.38 |
| Return on Invested Capital (ROIC) | 3.02 |
| Return on Capital Employed (ROCE) | 4.81 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.31 |
Taxes
Over the trailing twelve months, Teyi Pharmaceutical Group Co.,Ltd has paid 13.20M in income taxes, reflecting an effective tax rate of 19.13.
| Income Tax | 13.20M |
| Effective Tax Rate | 19.13 |
Stock Price Statistics
Teyi Pharmaceutical Group Co.,Ltd's stock has gained approximately 4.30233% over the past 52 weeks. The 50-day moving average sits at 9.11, while the 200-day moving average is 10.83.
| Beta (5Y) | N/A |
| 52-Week Price Change | 4.30233% |
| 50-Day Moving Average | 9.11 |
| 200-Day Moving Average | 10.83 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Teyi Pharmaceutical Group Co.,Ltd generated 865.18M in revenue and converted that into 55.81M in net income, yielding earnings per share of 0.11. EBITDA reached 81.58M, while operating income came in at 81.58M.
| Revenue | 865.18M |
| Gross Profit | 473.79M |
| Operating Income | 81.58M |
| Pretax Income | 69.01M |
| Net Income | 55.81M |
| EBITDA | 81.58M |
| EBIT | 81.58M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
Teyi Pharmaceutical Group Co.,Ltd holds 361.26M in cash and equivalents against 310.00M in total debt, resulting in a net debt position of 23.74M. Total book value stands at 879.18M, with working capital of 353.31M providing operational flexibility.
| Cash & Cash Equivalents | 361.26M |
| Total Debt | 310.00M |
| Net Debt | 23.74M |
| Equity (Book Value) | 879.18M |
| Book Value Per Share | 1.67 |
| Working Capital | 353.31M |
Cash Flow
After subtracting -88.35M in capital expenditures, free cash flow totaled -88.35M - equivalent to -0.17 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -88.35M |
| Free Cash Flow | -88.35M |
| FCF Per Share | -0.17 |
Margins
Teyi Pharmaceutical Group Co.,Ltd operates with a gross margin of 54.76, reflecting its pricing power and cost economics. The operating margin of 9.43 and net profit margin of 6.45 provide insight into operational efficiency.
| Gross Margin | 54.76 |
| Operating Margin | 9.43 |
| Pretax Margin | 7.98 |
| Profit Margin | 6.45 |
| EBITDA Margin | 9.43 |
Dividends & Yields
The company's payout ratio of 3.77 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | 3.77 |
| Shareholder Yield | 0.55 |
| FCF Yield | 2.00 |
Stock Splits
Teyi Pharmaceutical Group Co.,Ltd's most recent stock split took place on April 24, 2024 with a 5:7 split ratio.
| Last Split Date | 4/24/2024 |
| Split Ratio | 5:7 |
Scores
Teyi Pharmaceutical Group Co.,Ltd posts an Altman Z-Score of 6.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.59 |